Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Holding RVNC?
Track your performance easily
RVNC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.30 - $9.75
Previous Close$4.17
Volume1.21M
Average Volume (3M)3.47M
Market Cap
$437.44M
Enterprise Value$736.81M
Total Cash (Recent Filing)$184.08M
Total Debt (Recent Filing)$483.45M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Mar 04, 2025EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding104,902,388
10 Day Avg. Volume3,551,870
30 Day Avg. Volume3,473,844
Standard Deviation0.26
R-Squared0.04
Alpha0.00365
Financial Highlights & Ratios
Price to Book (P/B)-2.69
Price to Sales (P/S)1.83
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.98
Enterprise Value/Gross Profit4.61
Enterprise Value/Ebitda-7.49
Forecast
1Y Price Target
$6.73Price Target Upside61.39% Upside
Rating ConsensusHold
Number of Analyst Covering6
Revance Therapeutics News
PremiumCompany Announcements
Revance Therapeutics Reports Q3 Growth Amid Merger PlansBulls Say, Bears Say
Bulls Say
Financial PerformanceRevance recorded a total revenue of $59.9M, an increase of 10.7% YoY from $54.1M.
Merger ProgressThe continuation of dialogue between Revance and Crown indicates a willingness to negotiate, signaling potential progress towards the merger.
Strategic AgreementsRVNC announced it entered into an amended agreement with its partner Teoxane for the distribution of RHA fillers, with no items currently in dispute.
Bears Say
Financial PerformanceRevance's 3Q results came in far short of expectations with revenues at $59.9M vs consensus at $68.2M.
Market ConcernsRevance is facing allegations of material breaches in the RHA distribution agreement from Teoxane, which could lead to a lengthy arbitration process.
Merger UncertaintyFurther delays in the tender offer could complicate the closing of the merger, particularly due to the approaching multiple holidays.
---
Ownership Overview
1.90% Insiders
29.45% Mutual Funds
29.18% Other Institutional Investors
27.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVNC FAQ
What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $2.30 and its highest was $9.74 in the past 12 months.
What is Revance Therapeutics’s market cap?
Currently, no data Available
When is Revance Therapeutics’s upcoming earnings report date?
Revance Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 103 days.
How were Revance Therapeutics’s earnings last quarter?
Revance Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.269 by -$0.101.
Is Revance Therapeutics overvalued?
According to Wall Street analysts Revance Therapeutics’s price is currently Undervalued.
Does Revance Therapeutics pay dividends?
Revance Therapeutics does not currently pay dividends.
What is Revance Therapeutics’s EPS estimate?
Revance Therapeutics’s EPS estimate is -$0.19.
How many shares outstanding does Revance Therapeutics have?
Revance Therapeutics has 104,902,390 shares outstanding.
What happened to Revance Therapeutics’s price movement after its last earnings report?
Revance Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.269. Following the earnings report the stock price went down -35.986%.
Which hedge fund is a major shareholder of Revance Therapeutics?
Among the largest hedge funds holding Revance Therapeutics’s share is Perceptive Advisors LLC. It holds Revance Therapeutics’s shares valued at 2M.
---
Revance Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.73 (61.39% Upside)
$6.73 (61.39% Upside)
Blogger Sentiment
Neutral
RVNC Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 397.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.32%
Trailing 12-Months
Company Description
Revance Therapeutics
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
---
RVNC Earnings Call
Q2 2024
0:00 / 0:00
---
RVNC Stock 12 Month Forecast
Average Price Target
$6.73
▲(61.39% Upside)
Technical Analysis
Best Analysts Covering RVNC
1 Year
---